Understanding how low oxygen affects brain cell development in preterm infants
Glial HIFa: mechanisms and implications in hypoxia/ischemia-induced oligodendroglial pathology
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA AT DAVIS · NIH-11030227
This study is looking at how low oxygen levels affect the growth of important brain cells in premature babies, with a focus on a protein that helps these cells develop properly, in hopes of finding ways to support healthier brain development for these little ones.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA AT DAVIS (nih funded) |
| Locations | 1 site (DAVIS, UNITED STATES) |
| Trial ID | NIH-11030227 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms by which low oxygen levels impact the development of brain cells, specifically oligodendrocytes, in preterm infants who are at risk for brain injury. The study focuses on the role of a protein called HIFα in promoting the differentiation of oligodendrocyte progenitor cells into myelin-producing cells, which is crucial for healthy brain development. By exploring these molecular pathways, the research aims to identify potential therapeutic targets that could enhance myelination and improve outcomes for affected infants.
Who could benefit from this research
Good fit: Ideal candidates for this research are preterm infants born before 37 weeks of gestation who are at risk for brain injury due to hypoxia or ischemia.
Not a fit: Patients who are full-term infants or those without any signs of brain injury or myelination issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that promote healthy brain development and myelination in preterm infants, potentially reducing the incidence of neurological impairments.
How similar studies have performed: Previous research has shown promising results in understanding the role of HIFα in brain development, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
DAVIS, UNITED STATES
- UNIVERSITY OF CALIFORNIA AT DAVIS — DAVIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GUO, FUZHENG — UNIVERSITY OF CALIFORNIA AT DAVIS
- Study coordinator: GUO, FUZHENG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.